Posts

Vera’s IgAN Approval Kicks Off Competition with Otsuka

on

Otsuka touts new IgAN evidence as it seeks full approval for Voyxact

on

AstraZeneca's Ultomiris Meets Primary Endpoint in Phase III IgAN Trial, Reducing Proteinuria

on

Biogen Acquires Exclusive Rights to Felzartamab in Greater China Region from TJ Biopharma

on

FDA Grants Full Approval to Travere's Filspari for IgA Nephropathy

on

Vertex's Povetacicept Clears Phase 3 Milestone in IgA Nephropathy: Blockbuster Potential Ahead?

on

Vera Therapeutics Appoints Matt Skelton as Chief Commercial Officer

on

Vera Therapeutics Appoints James R. Meyers to Its Board of Directors

on

Otsuka's Anti-APRIL Antibody (Voyxact/Sibeprenlimab) Receives FDA Approval for IgA Nephropathy (IgAN)

on

Otsuka's Phase 3 IgAN Win with Sibeprenlimab Shakes Vera's Stock

on

FDA okays Novartis' second IgA nephropathy therapy Vanrafia

on

Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort

on

Fierce Pharma AsiaAstellas' first-in-class FDA nod; Otsuka's IgAN win; Samsung Bio's $1.2B contract

on